215 related articles for article (PubMed ID: 31196109)
1. Affordable and equitable access to subsidised outpatient medicines? Analysis of co-payments under the Additional Drug Package in Kyrgyzstan.
Vogler S; Schneider P; Dedet G; Bak Pedersen H
Int J Equity Health; 2019 Jun; 18(1):89. PubMed ID: 31196109
[TBL] [Abstract][Full Text] [Related]
2. Financial Burden of Prescribed Medicines Included in Outpatient Benefits Package Schemes: Comparative Analysis of Co-Payments for Reimbursable Medicines in European Countries.
Vogler S; Dedet G; Pedersen HB
Appl Health Econ Health Policy; 2019 Dec; 17(6):803-816. PubMed ID: 31506879
[TBL] [Abstract][Full Text] [Related]
3. Reasons why insured consumers co-pay for medicines at retail pharmacies in Pretoria, South Africa.
Mpanza NM; Bradley H; Laing R
Afr J Prim Health Care Fam Med; 2019 Mar; 11(1):e1-e6. PubMed ID: 31038333
[TBL] [Abstract][Full Text] [Related]
4. Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China.
Fang Y; Wagner AK; Yang S; Jiang M; Zhang F; Ross-Degnan D
Lancet Glob Health; 2013 Oct; 1(4):e227-37. PubMed ID: 25104348
[TBL] [Abstract][Full Text] [Related]
5. Towards equitable access to medicines for the rural poor: analyses of insurance claims reveal rural pharmacy initiative triggers price competition in Kyrgyzstan.
Waning B; Maddix J; Tripodis Y; Laing R; Leufkens HG; Gokhale M
Int J Equity Health; 2009 Dec; 8():43. PubMed ID: 20003422
[TBL] [Abstract][Full Text] [Related]
6. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia.
Hynd A; Roughead EE; Preen DB; Glover J; Bulsara M; Semmens J
Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1091-9. PubMed ID: 18942671
[TBL] [Abstract][Full Text] [Related]
7. Drug Policy in Bulgaria.
Dimova A; Rohova M; Atanasova E; Kawalec P; Czok K
Value Health Reg Issues; 2017 Sep; 13():50-54. PubMed ID: 29073988
[TBL] [Abstract][Full Text] [Related]
8. Balancing medicine prices and business sustainability: analyses of pharmacy costs, revenues and profit shed light on retail medicine mark-ups in rural Kyrgyzstan.
Waning B; Maddix J; Soucy L
BMC Health Serv Res; 2010 Jul; 10():205. PubMed ID: 20626904
[TBL] [Abstract][Full Text] [Related]
9. Availability, price and affordability of essential medicines for managing cardiovascular diseases and diabetes: a statewide survey in Kerala, India.
Satheesh G; Sharma A; Puthean S; Ansil T P M; E J; Raj Mishra S; Unnikrishnan MK
Trop Med Int Health; 2020 Dec; 25(12):1467-1479. PubMed ID: 32959441
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical policies: effects of cap and co-payment on rational drug use.
Austvoll-Dahlgren A; Aaserud M; Vist G; Ramsay C; Oxman AD; Sturm H; Kösters JP; Vernby A
Cochrane Database Syst Rev; 2008 Jan; (1):CD007017. PubMed ID: 18254125
[TBL] [Abstract][Full Text] [Related]
11. Prices of medicines for the management of pain, diabetes and cardiovascular diseases in private pharmacies and the national health insurance in Tanzania.
Kirua RB; Temu MJ; Mori AT
Int J Equity Health; 2020 Nov; 19(1):203. PubMed ID: 33172498
[TBL] [Abstract][Full Text] [Related]
12. Role of Cost on Failure to Access Prescribed Pharmaceuticals: The Case of Statins.
McRae I; van Gool K; Hall J; Yen L
Appl Health Econ Health Policy; 2017 Oct; 15(5):625-634. PubMed ID: 28660496
[TBL] [Abstract][Full Text] [Related]
13. Changes in Drug List Prices and Amounts Paid by Patients and Insurers.
Yang EJ; Galan E; Thombley R; Lin A; Seo J; Tseng CW; Resneck JS; Bach PB; Dudley RA
JAMA Netw Open; 2020 Dec; 3(12):e2028510. PubMed ID: 33295971
[TBL] [Abstract][Full Text] [Related]
14. Evaluating essential medicines for treating childhood cancers: availability, price and affordability study in Ghana.
Mensah KB; Mensah ABB; Bangalee V; Padayachee N; Oosthuizen F
BMC Cancer; 2021 Jun; 21(1):683. PubMed ID: 34112117
[TBL] [Abstract][Full Text] [Related]
15. The financial burden of out of pocket payments on medicines among households in Ethiopia: analysis of trends and contributing factors.
Mekuria GA; Ali EE
BMC Public Health; 2023 May; 23(1):808. PubMed ID: 37138248
[TBL] [Abstract][Full Text] [Related]
16. Inequalities in medicine use in Central Eastern Europe: an empirical investigation of socioeconomic determinants in eight countries.
Vogler S; Österle A; Mayer S
Int J Equity Health; 2015 Nov; 14():124. PubMed ID: 26541292
[TBL] [Abstract][Full Text] [Related]
17. Persistent low adherence to hypertension treatment in Kyrgyzstan: How can we understand the role of drug affordability?
Murphy A; Jakab M; McKee M; Richardson E
Health Policy Plan; 2016 Dec; 31(10):1384-1390. PubMed ID: 27315830
[TBL] [Abstract][Full Text] [Related]
18. Discounting of medicines in Australian community pharmacies.
Thai LP; Vitry AI; Moss JR
Aust Health Rev; 2014 Nov; 38(5):517-22. PubMed ID: 25099433
[TBL] [Abstract][Full Text] [Related]
19. Access to essential cardiovascular medicines for children: a pilot study of availability, price and affordability in Nigeria.
Orubu ESF; Robert FO; Samuel M; Megbule D
Health Policy Plan; 2019 Dec; 34(Supplement_3):iii20-iii26. PubMed ID: 31816074
[TBL] [Abstract][Full Text] [Related]
20. Community pharmacists' views about prescription medicine co-payments and potential implications for equitable access to medicines: a critical realist interpretation.
Peacocke EF; Fusheini A; Norris P
J Pharm Policy Pract; 2023 Nov; 16(1):156. PubMed ID: 38012721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
